Marie-Alix Poul
Inventor
Stats
- 2 US patents issued
- 5 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 2 US Patents Issued
- 5 US Applications Filed
- 24 Total Citation Count
- Nov 20, 2019 Most Recent Filing
- Nov 21, 1997 Earliest Filing
Work History
| Patent Owner | Applications Filed | Year |
|---|---|---|
| ECOLE NORMALE SUPERIEURE DE CACHAN | 1
1 | 2010
2014 |
| INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE | 1
| 1997
|
| UNIVERSITE DE MONTPELLIER | 1
1 | 2014
2015 |
| CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE | 1
1 | 1997
2014 |
| INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) | 1
1 | 2014
2015 |
| INSTITUT REGIONAL DU CANCER DE MONTPELLIER | 1
1 | 2014
2015 |
| UNIVERSITE PARIS-SUD | 1
1 | 2010
2014 |
| PROTEINE PERFORMANCE S.A. | 1
| 1997
|
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 1
| 2010
|
Inventor Addresses
| Address | Duration |
|---|---|
| Castries, FR | Feb 08, 05 - Feb 08, 05 |
| Montpelier Cedex 5, FR | Sep 15, 16 - Sep 15, 16 |
| Montpelier, FR | Apr 03, 18 - Apr 03, 18 |
| Montpellier Cedex 5, FR | Nov 30, 17 - Jun 15, 23 |
| Montpellier, FR | Feb 21, 13 - Sep 03, 19 |
Technology Profile
| Technology | Matters | |
|---|---|---|
| A61K: | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | 2 |
| A61P: | THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS | 2 |
| C07K: | PEPTIDES | 4 |
Patents / Publication
| Patents / Publication # | Year of Publication / Issued | Title | Citations |
|---|---|---|---|
| 2023/0183,379 | 2023 | BISPECIFIC ANTIBODY TARGETING TRANSFERRIN RECEPTOR 1 AND SOLUBLE ANTIGEN | 0 |
| 10398774 | 2019 | Human monoclonal antibodies against AXL | 0 |
| 9932410 | 2018 | Human neutralizing anti-kit antibodies and uses thereof | 0 |
| 2017/0340,734 | 2017 | HUMAN MONOCLONAL ANTIBODIES AGAINST AXL | 3 |
| 2016/0264,680 | 2016 | Human Neutralizing Anti-Kit Antibodies and Uses Thereof | 6 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.